Use of trimethoprim- sulfamethoxazole for treating Pneumocystis jirovecii pneumonia in a patient with glucose-6-phosphate dehydrogenase deficiency: a case report
BackgroundPneumocystis jirovecii pneumonia (PJP) is an opportunistic infection caused by the yeast-like fungus P. jirovecii. As recommended by some guidelines, the first-line treatment for this infection is trimethoprim-sulfamethoxazole (TMP-SMX), and the second-line treatment includes drugs such as...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2024-09-01
|
| シリーズ: | Frontiers in Medicine |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1443645/full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|